Welcome Dr. Janis Cotter of Parkway Sclerals
It is our honor to welcome Dr. Janis Cotter of Parkway Sclerals to our medical advisory board. Dr. Cotter has been fitting gas permeable scleral contact lenses to diseased eyes for almost 20 years received her doctorate in optometry in 1985 from the New England College of Optometry. She completed a residency in hospital based optometry at the VA Medical Center in West Roxbury and Brockton, Massachusetts. From 1986 to 1992 she was manager of the Contact Lens Service at Massachusetts Eye and Ear Infirmary, Boston, Massachusetts. It was here that she developed her interest and commitment to the use of contact lenses as medical devices for eye diseases. In 1992 she became executive director of a nonprofit foundation that specialized in the use of corneal and gas permeable scleral contact lenses for diseased eyes. Doctor Cotter was a member of the team that developed the Boston Scleral Lens. She was responsible for the clinical care of more than 500 patients fitted with the Boston Scleral lens during her 11 year association with the foundation. Doctor Cotter has been published nationally and internationally as well as lectured nationally and internationally on the use of gas permeable scleral contact lenses. Patients she has fitted with gas permeable scleral contact lenses were featured on Good Morning America, Oprah, and in multiple articles over the years. Janis M. Cotter, O.D

The SJS Foundation also welcomes: Dr. Scheffer Tseng to our Medical Advisory Board!
Dr. Tseng serves as Medical Director of Ocular Surface Center, providing the state-of-art to patients suffering from Stevens Johnson Syndrome and Toxic Epidermal Necrolysis. Dr. Tseng serves as Research Director of Ocular Surface Foundation, who are to be specialized in ocular surface biology, health, and diseases, and also director of Research & Development of TissueTech, Inc., Medical Director and Consultant of Bio-Tissue, Inc., and Director of Research & Development of Bio-Lipid, Inc., supervising a variety of directed to study the pathogenesis of ocular surface and tear diseases, and develop new tools and products for improving the diagnosis and treatment of these diseases.